» Articles » PMID: 34980540

Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study

Abstract

Background: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype.

Materials And Methods: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC).

Results: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant.

Conclusion: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women.

Citing Articles

Association between metabolic syndrome and cervical cancer among women in Southwestern Uganda: A case-control study.

Kajabwangu R, Ngonzi J, Izudi J, Bazira J, Ssedyabane F, Kanyesigye M Gynecol Oncol Rep. 2024; 54:101465.

PMID: 39139577 PMC: 11321433. DOI: 10.1016/j.gore.2024.101465.


Effect of metabolic syndrome and its components on the risk and prognosis of cervical cancer: A literature review.

Kajabwangu R, Izudi J, Bazira J, Ssedyabane F, Turanzomwe S, Birungi A Gynecol Oncol Rep. 2024; 54:101438.

PMID: 39035032 PMC: 11260376. DOI: 10.1016/j.gore.2024.101438.


Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy.

Matou-Nasri S, Aldawood M, Alanazi F, Khan A Diagnostics (Basel). 2023; 13(14).

PMID: 37510134 PMC: 10378597. DOI: 10.3390/diagnostics13142390.


Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis.

Bowo-Ngandji A, Kenmoe S, Ebogo-Belobo J, Kenfack-Momo R, Takuissu G, Kengne-Nde C PLoS One. 2023; 18(7):e0289155.

PMID: 37498832 PMC: 10374159. DOI: 10.1371/journal.pone.0289155.


Identification of Hub Genes and Biological Mechanisms Associated with Non-Alcoholic Fatty Liver Disease and Triple-Negative Breast Cancer.

Zhu J, Min N, Gong W, Chen Y, Li X Life (Basel). 2023; 13(4).

PMID: 37109526 PMC: 10146727. DOI: 10.3390/life13040998.


References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

2.
Athyros V, Ganotakis E, Elisaf M, Liberopoulos E, Goudevenos I, Karagiannis A . Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol. 2006; 117(2):204-10. DOI: 10.1016/j.ijcard.2006.04.078. View

3.
Gupta A, Oyekunle T, Salako O, Daramola A, Alatise O, Ogun G . Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study. Oncotarget. 2021; 12(13):1230-1242. PMC: 8238238. DOI: 10.18632/oncotarget.27991. View

4.
Renehan A, Tyson M, Egger M, Heller R, Zwahlen M . Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X. View

5.
Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View